14 DALAL STREET INVESTMENT JOURNAL I JULY 22 - AUG 4, 2019 DSIJ.in^
210220230240250260270280290(Closing price as of July 16, 2019)The scrips in this
column have been
recommended
with a 15-day investment
horizon in mind and
carry high risk. Therefore,
investors are advised to
take into account their risk
appetite before investing,
as fundamentals may
or may not back the
recommendations.SUN PHARMACEUTICAL INDUSTRIES LTD.
BRIGADE ENTERPRISES LTD
BSE CODE
532929BSE CODE
524715Volume
23,Volume
506,Face Value
` 10Face Value
` 1Target
` 295Target
` 470Stoploss
`257 (CLS)Stoploss
`400 (CLS)CMP - `272.CMP - `433.B
rigade Enterprises Ltd is engaged in
developing residential, commercial
and retail properties primarily in
Bangalore and Mysore, and has also
developed and is managing a number of
serviced apartments under the brand,
Brigade Homestead. The company has a
uniquely diverse multi-domain portfolio
that covers property development,
property management services, hospitality
and education. The company also engaged
in the business of real estate, hospitality,
lease rentals. On the financial front, the net
sales grew 58 per cent in Q4FY19 YoY to
`464.57 crore. The PBIDT rose 40 per cent
to `142.71 crore in Q4FY19 as compared to
`102.5 crore posted in the same period of
the previous year. The PAT rose 50 per cent
to `65.25 crore in Q4FY19 from `43.
crore posted in Q4FY18. Of recent, Brigade
Enterprises is planning to increase the
authorised share capital of the company
from `150 crore divided into 15 croreS
un Pharmaceuticals Industries Limited
is a pharmaceutical company having US
business, Indian branded generics
business, emerging markets, global consum-
er healthcare business and active pharma-
ceutical ingredients (APIs). The company
manufactures generics, branded generics,
specialty products, over-the-counter (OTC)
products, anti-retroviral (ARVs), APIs and
intermediates in a range of dosage forms,
which include tablets, capsules, injectables,
ointments, creams and liquids. On the
financial front, the company reported net
sales of `2,552.13 crore for Q4FY19, an
increase by 11.78 per cent compared to
`2,283.18 crore for Q4FY18. The PBDT for
Q4FY19 stood at `1,118.36 crore, a signifi-
cant increase by 326.01 per cent from
`262.52 crore for Q4FY18. The PAT rose by
505.96 per cent in Q4FY19 to `1,068.06 crore
from `176.26 crore in Q4FY18. The com-
pany’s net sales increased by 29.64 per cent in
FY19 to `10,303.21 crore from `7,947.
crore in FY18. We recommend a BU Y.Scrip’s MovementLast Seven Days’ Volume Table
(No. of Shares)
Days Volume
08-Jul-19 16,
09-Jul-19 5,
10-Jul-19 6,
11-Jul-19 7,
12-Jul-19 2,
15-Jul-19 6,
16-Jul-19 23,320340360380400420440Scrip’s MovementLast Seven Days’ Volume Table
(No. of Shares)
Days Volume
08-Jul-19 4,90,
09-Jul-19 9,11,
10-Jul-19 6,15,
11-Jul-19 4,90,
12-Jul-19 7,02,
15-Jul-19 10,47,
16-Jul-19 5,06,834 D
S20192019equity shares of `10 each to `250 crore
divided into 25 crore equity shares of
`10 each. We recommend a BU Y.Recommendations Equity